Rezolve Ai PLC reaffirmed its FY26 revenue guidance of approximately $360 million, reflecting a 7.5x year-on-year growth driven by strong enterprise adoption of its AI-powered commerce solutions. The company generated $60 million in Q1 2026, surpassing its full-year 2025 revenue of $46.8 million, and now serves over 1,000 enterprise customers globally. Rezolve Ai's technology, including its brainpowa model and TraceWare validation system, supports the shift in retail from traditional search to conversational and autonomous commerce. With strategic partnerships and a growing commercial pipeline, Rezolve Ai positions itself as a key player in the $30 trillion global retail transformation led by AI.
A KAYAK survey of 2,000 Brazilian travelers revealed Cristiano Ronaldo as the most desired football companion for trips, chosen by 60% of respondents. Vinícius Júnior and Endrick followed with 19% and 9%, respectively. The Northeast region of Brazil,...
A KAYAK survey of 2,000 Brazilian travelers found Cristiano Ronaldo is the most desired football player to travel with, chosen by 60% of respondents. Vinícius Júnior and Endrick followed with 19% and 9% respectively. Most Brazilians (59%) would take ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Oryn Therapeutics is progressing its next-generation Orynotide™ macrocyclic peptide platform aimed at treating inflammatory and autoimmune diseases through immune reprogramming rather than suppression. The company appointed Guy Rosenthal as CEO and e...
Myriad Genetics has broadened the availability of its Precise MRD test to include breast, colorectal, and renal cancers, impacting over 6 million U.S. patients. The test uses whole-genome sequencing to track tumor DNA with high sensitivity, aiding tr...
